234 related articles for article (PubMed ID: 35728869)
1. WT1-specific TCRs directed against newly identified peptides install antitumor reactivity against acute myeloid leukemia and ovarian carcinoma.
van Amerongen RA; Hagedoorn RS; Remst DFG; Assendelft DC; van der Steen DM; Wouters AK; van de Meent M; Kester MGD; de Ru AH; Griffioen M; van Veelen PA; Falkenburg JHF; Heemskerk MHM
J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35728869
[TBL] [Abstract][Full Text] [Related]
2. PRAME and CTCFL-reactive TCRs for the treatment of ovarian cancer.
van Amerongen RA; Tuit S; Wouters AK; van de Meent M; Siekman SL; Meeuwsen MH; Wachsmann TLA; Remst DFG; Hagedoorn RS; van der Steen DM; de Ru AH; Verdegaal EME; van Veelen PA; Falkenburg JHF; Heemskerk MHM
Front Immunol; 2023; 14():1121973. PubMed ID: 37026005
[TBL] [Abstract][Full Text] [Related]
3. T-cell responses directed against multiple HLA-A*0201-restricted epitopes derived from Wilms' tumor 1 protein in patients with leukemia and healthy donors: identification, quantification, and characterization.
Rezvani K; Brenchley JM; Price DA; Kilical Y; Gostick E; Sewell AK; Li J; Mielke S; Douek DC; Barrett AJ
Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8799-807. PubMed ID: 16361568
[TBL] [Abstract][Full Text] [Related]
4. CRISPR-based gene disruption and integration of high-avidity, WT1-specific T cell receptors improve antitumor T cell function.
Ruggiero E; Carnevale E; Prodeus A; Magnani ZI; Camisa B; Merelli I; Politano C; Stasi L; Potenza A; Cianciotti BC; Manfredi F; Di Bono M; Vago L; Tassara M; Mastaglio S; Ponzoni M; Sanvito F; Liu D; Balwani I; Galli R; Genua M; Ostuni R; Doglio M; O'Connell D; Dutta I; Yazinski SA; McKee M; Arredouani MS; Schultes B; Ciceri F; Bonini C
Sci Transl Med; 2022 Feb; 14(631):eabg8027. PubMed ID: 35138911
[TBL] [Abstract][Full Text] [Related]
5. Allogeneic HLA-A*02-restricted WT1-specific T cells from mismatched donors are highly reactive but show off-target promiscuity.
Falkenburg WJ; Melenhorst JJ; van de Meent M; Kester MG; Hombrink P; Heemskerk MH; Hagedoorn RS; Gostick E; Price DA; Falkenburg JH; Barrett AJ; Jedema I
J Immunol; 2011 Sep; 187(5):2824-33. PubMed ID: 21821799
[TBL] [Abstract][Full Text] [Related]
6. Biased usage of BV gene families of T-cell receptors of WT1 (Wilms' tumor gene)-specific CD8+ T cells in patients with myeloid malignancies.
Tanaka-Harada Y; Kawakami M; Oka Y; Tsuboi A; Katagiri T; Elisseeva OA; Nishida S; Shirakata T; Hosen N; Fujiki F; Murao A; Nakajima H; Oji Y; Kanda Y; Kawase I; Sugiyama H
Cancer Sci; 2010 Mar; 101(3):594-600. PubMed ID: 20132220
[TBL] [Abstract][Full Text] [Related]
7. Peptide epitopes from the Wilms' tumor 1 oncoprotein stimulate CD4+ and CD8+ T cells that recognize and kill human malignant mesothelioma tumor cells.
May RJ; Dao T; Pinilla-Ibarz J; Korontsvit T; Zakhaleva V; Zhang RH; Maslak P; Scheinberg DA
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4547-55. PubMed ID: 17671141
[TBL] [Abstract][Full Text] [Related]
8. Generation of donor-derived Wilms tumor antigen 1-specific cytotoxic T lymphocytes with potent anti-leukemia activity for somatic cell therapy in children given haploidentical stem cell transplantation: a feasibility pre-clinical study.
Ferulli F; Tanzi M; Turin I; Montini E; Rosti V; Acquafredda G; Lisini D; Compagno F; Boghen S; Licari A; Marseglia G; Zecca M; Montagna D
Cytotherapy; 2019 Sep; 21(9):958-972. PubMed ID: 31279696
[TBL] [Abstract][Full Text] [Related]
9. Targeting intracellular WT1 in AML with a novel RMF-peptide-MHC-specific T-cell bispecific antibody.
Augsberger C; Hänel G; Xu W; Pulko V; Hanisch LJ; Augustin A; Challier J; Hunt K; Vick B; Rovatti PE; Krupka C; Rothe M; Schönle A; Sam J; Lezan E; Ducret A; Ortiz-Franyuti D; Walz AC; Benz J; Bujotzek A; Lichtenegger FS; Gassner C; Carpy A; Lyamichev V; Patel J; Konstandin N; Tunger A; Schmitz M; von Bergwelt-Baildon M; Spiekermann K; Vago L; Jeremias I; Marrer-Berger E; Umaña P; Klein C; Subklewe M
Blood; 2021 Dec; 138(25):2655-2669. PubMed ID: 34280257
[TBL] [Abstract][Full Text] [Related]
10. Simultaneous in vitro generation of CD8 and CD4 T cells specific to three universal tumor associated antigens of WT1, survivin and TERT and adoptive T cell transfer for the treatment of acute myeloid leukemia.
Sohn HJ; Lee JY; Lee HJ; Sohn DH; Cho HI; Kim HJ; Kim TG
Oncotarget; 2017 Jul; 8(27):44059-44072. PubMed ID: 28477011
[TBL] [Abstract][Full Text] [Related]
11. A High-avidity WT1-reactive T-Cell Receptor Mediates Recognition of Peptide and Processed Antigen but not Naturally Occurring WT1-positive Tumor Cells.
Jaigirdar A; Rosenberg SA; Parkhurst M
J Immunother; 2016 Apr; 39(3):105-16. PubMed ID: 26938944
[TBL] [Abstract][Full Text] [Related]
12. Wilms' Tumour 1 (WT1) peptide vaccination in patients with acute myeloid leukaemia induces short-lived WT1-specific immune responses.
Uttenthal B; Martinez-Davila I; Ivey A; Craddock C; Chen F; Virchis A; Kottaridis P; Grimwade D; Khwaja A; Stauss H; Morris EC
Br J Haematol; 2014 Feb; 164(3):366-75. PubMed ID: 24422723
[TBL] [Abstract][Full Text] [Related]
13. Lentivirus-induced dendritic cells for immunization against high-risk WT1(+) acute myeloid leukemia.
Sundarasetty BS; Singh VK; Salguero G; Geffers R; Rickmann M; Macke L; Borchers S; Figueiredo C; Schambach A; Gullberg U; Provasi E; Bonini C; Ganser A; Woelfel T; Stripecke R
Hum Gene Ther; 2013 Feb; 24(2):220-37. PubMed ID: 23311414
[TBL] [Abstract][Full Text] [Related]
14. Recognition of a natural WT1 epitope by a modified WT1 peptide-specific T-cell receptor.
Tamanaka T; Oka Y; Fujiki F; Tsuboi A; Katsuhara A; Nakajima H; Hosen N; Nishida S; Lin YH; Tachino S; Akatsuka Y; Kuzushima K; Oji Y; Kumanogoh A; Sugiyama H
Anticancer Res; 2012 Dec; 32(12):5201-9. PubMed ID: 23225417
[TBL] [Abstract][Full Text] [Related]
15. Novel adoptive T-cell immunotherapy using a WT1-specific TCR vector encoding silencers for endogenous TCRs shows marked antileukemia reactivity and safety.
Ochi T; Fujiwara H; Okamoto S; An J; Nagai K; Shirakata T; Mineno J; Kuzushima K; Shiku H; Yasukawa M
Blood; 2011 Aug; 118(6):1495-503. PubMed ID: 21673345
[TBL] [Abstract][Full Text] [Related]
16. Human cytotoxic T-lymphocyte responses specific for peptides of the wild-type Wilms' tumor gene (WT1 ) product.
Oka Y; Elisseeva OA; Tsuboi A; Ogawa H; Tamaki H; Li H; Oji Y; Kim EH; Soma T; Asada M; Ueda K; Maruya E; Saji H; Kishimoto T; Udaka K; Sugiyama H
Immunogenetics; 2000 Feb; 51(2):99-107. PubMed ID: 10663572
[TBL] [Abstract][Full Text] [Related]
17. Combining CRISPR-Cas9 and TCR exchange to generate a safe and efficient cord blood-derived T cell product for pediatric relapsed AML.
Lo Presti V; Meringa A; Dunnebach E; van Velzen A; Moreira AV; Stam RW; Kotecha RS; Krippner-Heidenreich A; Heidenreich OT; Plantinga M; Cornel A; Sebestyen Z; Kuball J; van Til NP; Nierkens S
J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38580329
[TBL] [Abstract][Full Text] [Related]
18. Induction of complete and molecular remissions in acute myeloid leukemia by Wilms' tumor 1 antigen-targeted dendritic cell vaccination.
Van Tendeloo VF; Van de Velde A; Van Driessche A; Cools N; Anguille S; Ladell K; Gostick E; Vermeulen K; Pieters K; Nijs G; Stein B; Smits EL; Schroyens WA; Gadisseur AP; Vrelust I; Jorens PG; Goossens H; de Vries IJ; Price DA; Oji Y; Oka Y; Sugiyama H; Berneman ZN
Proc Natl Acad Sci U S A; 2010 Aug; 107(31):13824-9. PubMed ID: 20631300
[TBL] [Abstract][Full Text] [Related]
19. Safety and persistence of WT1-specific T-cell receptor gene-transduced lymphocytes in patients with AML and MDS.
Tawara I; Kageyama S; Miyahara Y; Fujiwara H; Nishida T; Akatsuka Y; Ikeda H; Tanimoto K; Terakura S; Murata M; Inaguma Y; Masuya M; Inoue N; Kidokoro T; Okamoto S; Tomura D; Chono H; Nukaya I; Mineno J; Naoe T; Emi N; Yasukawa M; Katayama N; Shiku H
Blood; 2017 Nov; 130(18):1985-1994. PubMed ID: 28860210
[TBL] [Abstract][Full Text] [Related]
20. Mutated nucleophosmin 1 as immunotherapy target in acute myeloid leukemia.
van der Lee DI; Reijmers RM; Honders MW; Hagedoorn RS; de Jong RC; Kester MG; van der Steen DM; de Ru AH; Kweekel C; Bijen HM; Jedema I; Veelken H; van Veelen PA; Heemskerk MH; Falkenburg JHF; Griffioen M
J Clin Invest; 2019 Feb; 129(2):774-785. PubMed ID: 30640174
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
